Drug Trial Radar · NCT04718389
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,717
Actual
Start
Jan 26, 2021
Primary completion
Sep 14, 2025
Study completion Sep 14, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Conditions
- Asthma
Interventions
GSK3511294 (Depemokimab)Biological
GSK3511294 (Depemokimab) 100 mg SC along with the placebo and SOC will be administered.
MepolizumabBiological
Mepolizumab 100 mg SC will be administered in a single-use PFS.
BenralizumabBiological
Benralizumab 30 mg will be administered in a single-use PFS.
PlaceboBiological
Placebo will be a sterile liquid formulation.
Standard of care (SoC)Drug
Non-biologic SoC will include inhaled corticosteroid (ICS) plus at least one other controller, long-acting beta-2-agonist (LABA), long-acting muscarinic antagonist (LAMA), with or without maintenance oral corticosteroids (OCS).
Pre-filled Syringes (PFS)Device
PFS will include glass barrel with pre-staked needle and plunger.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Clinically Significant Exacerbations Over 52 WeeksTime frame: Up to Week 52
Locations
397 sites in 21 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Scottsboro, Alabama
GSK Investigational Site
Litchfield Park, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Oxnard, California
GSK Investigational Site
Rancho Cucamonga, California
GSK Investigational Site
Redondo Beach, California
GSK Investigational Site
Redwood City, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Valencia, California
GSK Investigational Site
Woodland, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Kissimmee, Florida
GSK Investigational Site
Loxahatchee Groves, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
Showing 40 of 397 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.